Dolastatin 15 derivatives

MYPI1998003298A0Inactive Publication Date: 1999-01-18ABBOTT GMBH & CO KG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI1998003298
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
1997-07-18
Filing Date
1998-07-18
Publication Date
1999-01-18
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Dolastatin 15, a potent inhibitor of cell growth, is difficult to isolate from the sea hare Dolabella auricularia due to its trace quantities and expensive synthesis, and it suffers from poor aqueous solubility, limiting its practical application as a cancer treatment.

Method used

Development of structurally modified Dolastatin 15 derivatives with improved aqueous solubility and reduced production costs, retaining or enhancing antineoplastic activity, which can be synthesized efficiently and administered as pharmaceutical compositions for cancer treatment.

Benefits of technology

The modified peptides exhibit enhanced therapeutic potential for treating neoplastic diseases with improved solubility and cost-effectiveness, offering a viable alternative to natural Dolastatin 15 for cancer therapy.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

COMPOUNDS OF THE PRESENT INVENTION INCLUDE CELL GROWTH INHIBITORS WHICH ARE PEPTIDES OF FORMULA I, A - B - D - E - F - (G) r -(K) s - L (I) AND ACID SALTS THEREOF, WHEREIN A, B, D, E, F, G AND K ARE ?-AMINO ACID RESIDUES, AND S AND R ARE EACH, INDEPENDENTLY, 0 OR 1. L IS A MONOVALENT RADICAL, SUCH AS, FOR EXAMPLE, AN AMINO GROUP, AN N-SUBSTITUTED AMINO GROUP, A ?- HYDROXYLAMINO GROUP, A HYDRAZIDO GROUP, AN ALKOXY GROUP, A THIOALKOXY GROUP, AN AMINOXY GROUP, OR AN OXIMATO GROUP. THE PRESENT INVENTION ALSO INCLUDES A METHOD FOR TREATING CANCER IN A MAMMAL, SUCH AS A HUMAN, COMPRISING ADMINISTERING TO THE MAMMAL AN EFFECTIVE AMOUNT OF A COMPOUND OF FORMULA I IN A PHARMACEUTICALLY ACCEPTABLE COMPOSITION.
Need to check novelty before this filing date? Find Prior Art

Description

DOLASTATIN 15 DERIVATIVESBACKGROUND OF THE INVENTIONA number of short peptides with significant activity as inhibitors of cell growth have been isolated from the Indian Ocean sea hare Dolabella auricularia (Bai et al., Biochem. Pharmacology,40: 1859-1864 (1990); Beckwith et al. , J. Natl. Cancer Inst., 85: 483-488 (1993) and references cited therein). These include Dolastatins 1-10 (U.S. Patent No. 4,816,444, issued to Pettit et al.) and Dolastatin-15 (European Patent Application No. 3 98558) . Dolastatin 15, for example, markedly inhibits the growth of the National Cancer Institute’s P388 lymphocytic leukemia (PS system) cell line, a strong predictor of efficacy against various types of human malignancies.The exceedingly small amounts of the various Dolastatin peptides present in Dolabella auricularia (about 1 mg each per 100 kg sea hare) and the consequent difficulties in purifying amounts sufficient for evaluation and use, have motivated efforts toward the synthesis of these compounds (Roux et al. , Tetrahedron 50: 5345-5360 (1994); Shioiri et al., Tetrahedron 49: 1913-24 (1993); Patino et al., Tetrahedron 48: 4115-4122 (1992) and references cited therein). Synthetic Dolastatin 15, however, suffers from drawbacks which include poor solubility in aqueous systems and the need for expensive starting materials for its synthesis. These, in turn, have led to the synthesis and evaluation of structurally modified Dolastatin 15 derivatives [cf.: Biorg. Med. Chem. Lett. 4: 1947-50' (1994) ; WO 93 03054; JP-A-06234790; WO 93 23424] .However, there is a need for synthetic compounds with the biological activity of Dolastatin 15 which have useful aqueous solubility and can be produced efficiently and economically.SUMMARY OF THE INVENTIONCompounds of the present invention include cell growth inhibitors which are peptides of Formula I,A-B-D-E-F- (G)r- (K)s- L (I), and acid salts thereof, wherein A, B, D, E, F, G and K are α-amino acid residues, and s and r are each, independently, 0 or 1. L is a monovalent radical, such as, for example, an amino group, an N-substituted amino group, a βhydroxylamino group, a hydrazido group, an alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group.Another aspect of the present invention includes pharmaceutical compositions comprising a compound of Formula I and a pharmaceutically acceptable carrier.An additional embodiment of the present invention is a method for treating cancer in a mammal, such as a human, comprising administering to the mammal an effective amount of a compound of Formula I in a pharmaceutically acceptable ίcomposition.DETAILED DESCRIPTION OF THE INVENTIONThe present invention relates to peptides having antineoplastic activity. It also includes pharmaceutical compositions comprising these compounds and methods for treating cancer in a mammal, including a human, by administration of these compositions to the mammal.Dolastatin 15, a peptide isolated from the sea hare Dolabella auricularia, is a potent inhibitor of cell growth. This compound, however, is present in trace quantities in the sea hare, and is thus difficult to isolate. Dolastatin 15 is also expensive to synthesize and suffers from poor aqueous solubility. As shown herein, however, Dolastatin 15 can serve as a starting point for the development of compounds which overcome these disadvantages while retaining antineoplastic activity or exhibiting greater antineoplastic activity than the natural product. Applicants have discovered that certain structural modifications of Dolastatin 15 provide compounds with a surprisingly improved therapeutic potential for the treatment of neoplastic diseases as compared to Dolastatin 10 and Dolastatin 15. Furthermore, the compounds of the present invention can be conveniently synthesized, as described below in detail.For the purposes of the present invention, the term monovalent radical is intended to mean an electrically neutral molecular fragment capable of forming one covalent bond with a second neutral molecular fragment. Monovalent radicals include the hydrogen atom, alkyl groups, such as methyl, ethyl and propyl groups, halogen atoms, such as fluorine, chlorine and bromine atoms, aryl groups, such as phenyl and naphthyl groups, and alkoxy groups, such as methoxy and ethoxy groups. Two monovalent radicals on adjacent sigma-bonded atoms can also together form a pi bond between the adjacent atoms. Two monovalent radicals may also be linked together, for example, by a polymethylene unit, to form a cyclic structure. For example, the unit -N(R)R’, wherein R and R' are each a monovalent radical, can, together with the nitrogen atom, form a heterocyclic ring. In addition, two monovalent radicals bonded to the same atom can together form a divalent radical, such as an oxygen atom or an alkylidene group, for example, a propylidene group.For the purposes of the present invention, the term normal alkyl refers to an unbranched, or straight chain, alkyl group, for example, normal propyl (n-propyl, CH2CH2CH3) .The compounds of the present invention can be represented by Formula I,A - B - D - E - F - (G)r- (K)s- L (I), wherein A, B, D, E, F, G, and K are α-amino acid residues; s and r are each, independently, 0 or 1; and L is a monovalent radical such as an amino group, an N-substituted amino group, a β-hydroxylamino group, a hydrazido group,an-5alkoxy group, a thioalkoxy group, an aminoxy group, or an oximato group.The peptides of Formula I are generally composed of L-amino acids but they can contain one or more D-amino acids. In the following discussion, reference to a particular amino acid includes both enantiomers unless a specific enantiomer is indicated. The present compounds can also be present as salts with physiologicallycompatible acids, including hydrochloric acid, citric acid, tartaric acid, lactic acid, phosphoric acid, methanesulfonic acid, acetic acid, formic acid, maleic acid, fumaric acid, malic acid, succinic acid, malonic acid, sulfuric acid, L-glutamic acid, L-aspartic acid, pyruvic acid, mucic acid, benzoic acid, glucuronic acid, oxalic acid, ascorbic acid and acetylglycine.The following is a description of the present invention, including a detailed description of individual components and of methods of using the claimed compounds.Compounds of the Present InventionIdentity of AIn one embodiment, A is a proline derivative of Formula IIa,CII ου.-6where nais an integer, preferably 0, 1, 2, or 3. Rais a monovalent radical, such as a hydrogen atom or an unsubstituted or fluorine-substituted alkyl group, for example a normal, branched or cyclic C1-C3-alkyl group which is, optionally, substituted by from 1 to about 3 fluorine atoms; suitable examples include methyl, ethyl, isopropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl,1-methyl-2-fluoroethyl, 1-fluoromethyl-2-fluoroethyl or cyclopropyl;, methyl, ethyl or isopropyl are preferred;In this embodiment, R1a is a monovalent radical, such as a hydrogen atom, an alkyl group, such as a methyl, ethyl or propyl group, or a phenyl group. The phenyl group can be’substituted; suitable substituents include one or more halogen atoms, with fluorine, chlorine and bromine atoms preferred, Ci-^-alkyl groups, methoxy, ethoxy, trifluoromethyl or nitro groups. Raand Rxa together can also form a propylene bridge.R2a, R3a, R4a and R5a are each, independently, a monovalent radical, such as a hydrogen atom or an alkyl, preferably, methyl, group.In another embodiment, A is a substituted glycine derivative of Formula IIIa,R, O (Νϋ where Rahas the meaning stated for Rain Formula IIaand, 25 R1a is a monovalent radical, for example, a hydrogen atom-Ί or a Ci-Cg-alkyl group, preferably a methyl, ethyl or propyl group.In this embodiment, R6a is a monovalent radical, such as an alkyl, substituted alkyl, alkenyl, phenyl or substituted phenyl group. Suitable examples include methoxymethyl, 1-methoxyethyl, 1,1-dimethyl-hydroxymethyl, 1-trifluoromethylethyl, 1-trifluoromethyl-2,2,2trifluoroethyl, vinyl, and 1-methylvinyl. Phenyl substituents can include one or more halogen atoms, preferably fluorine, chlorine or bromine atoms, and alkyl, methoxy, ethoxy, trifluoromethyl, and nitro groups.When Rla is an alkyl group, R6a can also be a C^-Cgalkyl, cycloalkyl, unsubstituted benzyl or substituted benzyl group. Suitable benzyl substituents include one or more halogen atoms, such as fluorine, chlorine or bromine atoms, C1-C4-alkyl groups, and methoxy, ethoxy, trifluoromethyl and nitro groups.R7a is a monovalent radical, preferably a methyl, ethyl or isopropyl group.In another embodiment, A is an α-amino acid derivative of Formula IVa,O-8where mais an integer, preferably 1 or 2, and Raand R7a have the meanings stated for these substituents in Formula IIIa.In another embodiment, A is an α-amino acid derivative 5 of Formula Va,(Va), where Raand R7a have the meanings stated for Raand R7a in Formula IIIa.In a further embodiment, A is a substituted proline 10 derivative of Formula VIa,-9where Raand Rxa have the meanings stated for Raand R1a in Formula IIa, and Xais a monovalent radical, preferably a hydroxyl, alkoxy, for example, methoxy or ethoxy, group or a fluorine atom.In another embodiment, A is a thiaprolyl derivative of Formula VI Ia,where Ra, R1a, R2a, R3a, R4a and R5a have the meanings stated for the respective substituents in Formula IIa.In another embodiment, A is a 1,3-dihydroisoindole derivative of Formula VIIIaII o(VIII,)-10where Rahas the meaning stated for Rafor Formula IIa.In another embodiment, A is a2-azabicyclo [2.2.1] heptane-3-carboxylic acid derivative of Formula IXa,Ra where Zais a single or double bond and Rahas the meaning stated for Formula IIa. The 3-carbonyl substituent can have either the exo or endo orientation.In another embodiment, A is an α-amino acid derivative 10 of Formula Xa,where nahas the meaning as stated for nafor Formula IIa, and R7a and Rahave the meanings as stated for R7a and Rafor Formula IIIa.-11Xdentity of BB is a valyl, isoleucyl, allo-isoleucyl, norvalyl, 2tert-butylglycyl or 2-ethylglycyl residue. B can also be an a-amino acid residue of Formula IIb,ou.1 .in which Rband Rbare each a monovalent radical. Rbis, preferably, a hydrogen atom and R2b is, for example, an alkyl, alkoxyalkyl or alkenyl group. In preferred embodiments, R2b is a cyclopropyl group, a normal or branched butyl, preferably tertiary-butyl, group, a methoxymethyl group, a 1-methoxyethyl group or a 1-methylvinyl group. Additionally, Rxb and R2b together can be an isopropylidene group.Identity of DD is an N-alkylvalyl, N-alkyl-2-ethylglycyl, Nalkyl-2-tert-butylglycyl, N-alkyl-norleucyl, N-alkylisoleucyl, N-alkyl-allo-isoleucyl or N-alkyl-norvalyl residue, where the N-alkyl group is preferably a methyl group or an ethyl group.In another embodiment, D is an α-amino acid residue of Formula IId,Rd Ο where has the meaning stated for Rain Formula IIIa, R^ is a monovalent radical, preferably a hydrogen atom, and R2d is a monovalent radical, for example, an alkyl, alkoxyalkyl or alkenyl group. In preferred embodiments, R2d is a cyclopropyl group, a normal or branched butyl, preferably tertiary-butyl, group, a methoxymethyl group, a 1-methoxyethyl group or a 1-methylvinyl group, such as a cyclopropyl group, a methoxymethyl group, a 1-methoxyethyl group or a 1-methyl vinyl group. Additionally, Rxd and R2d together can form an isopropylidene group.Alternatively, D can be a proline derivative of Formula IIId,(HU.-13where ndis an integer, for example, 1 or 2, and R3d has the meaning stated for R1a in Formula IIIa. Xdis a monovalent radical, preferably a hydrogen atom, and, in the case where ndequals 1, can also be a hydroxy or alkoxy, for example, methoxy or ethoxy, group or a fluorine atom.Identity of EE is a prolyl, thiazolidinyl-4-carbonyl, homoprolyl or hydroxyprolyl residue, or a cyclic α-amino carboxylic acid residue of Formula IIe,II where neis an integer, preferably 0, 1 or 2. Rxe has the meaning stated for R1a in Formula IIIa. R2e and R3e are each a monovalent radical, and can be, independently, a hydrogen atom or an alkyl, preferably methyl, group. R4e is a monovalent radical, preferably a hydrogen atom, a hydroxy, alkoxy, for example, methoxy or ethoxy, group or a fluorine atom. R5e is a monovalent radical, preferably a hydrogen atom or a fluorine atom. In the case where nais1, R3e and R4e can together form a double bond, or R4e andRse can together be a double-bonded oxygen radical. In the-14case where nehas the value 1 or 2, Rle and R2e can together form a double bond.In another embodiment, E is a 2- or 3-aminocyclopentanecarboxylic acid residue of Formula IIIa,where Reis an alkyl group, such as methyl or ethyl, and Rxe has the meaning stated for Rla in Formula IIIa.Identity of FF is a prolyl, thiazolidinyl-4-carbonyl, homoprolyl or 10 hydroxyprolyl residue. F can also be a cyclic α-amino acid residue of Formula IIf,R2, (Ilf).-15where ncis an integer, preferably 0, l or 2. r\ has the meaning stated for R1a in Formula IIIa. R2C and R3C are each a monovalent radical, and can be, independently, a hydrogen atom or an alkyl, preferably methyl, group. R4f.is a monovalent radical, preferably a hydrogen atom, a hydroxy, alkoxy, for example, methoxy or ethoxy, group or a fluorine atom. R5C is a monovalent radical, preferably a hydrogen atom or a fluorine atom. In the case where nfhas the value 1, R3f and R4C together can form a double bond orR4f and Rsc can together be a double-bonded oxygen radical. In the case where nfhas the value 1 or 2, R1^ and R2f can together form a double bond.In another embodiment, F is a 2- or 3-aminocyclopentanecarboxylic acid residue of Formula IIICwhere Rfis a monovalent radical, such as a methyl or ethyl group, and r\ has the meaning stated for R1a in- FormulaIII..In another embodiment, F is an N-alkylglycyl or N20 alkylalanyl residue, and the alkyl group is, preferably, a methyl group or an ethyl group.-16Identity of GG is an α-amino acid residue of Formula IIg,(Hg), wherein R1g is a hydrogen atom, or an alkyl group, for example, methyl, ethyl or n-propyl. R2g can be, for example, a hydrogen atom, or an alkyl, arylalkyl, heteroarylalkyl or aryl group. Preferably, R2g is an ethyl, isopropyl, tert-butyl, isobutyl, 2-methylpropyl, cyclohexylmethyl, benzyl, 'thiazolyl-2-methyl, pyridyl-2methyl, n-butyl, 2,2-dimethylpropyl, naphthylmethyl, or npropyl group, or a substituted or unsubstituted phenyl group. Suitable phenyl substituents include one or more halogen, preferably fluorine, chlorine or bromine, atoms,C]_-C4-alkyl groups, methoxy, ethoxy, nitro or trifluoromethyl groups or a dioxomethylene group. Alternately, Rxg and R2g can, together with the a-carbon atom, form a cyclopentane or cyclohexane ring or a benzofused cyclopentane ring, such as, for example, the indanyl group.-17Identity of KK is an α-amino acid residue of Formula IIk,wherein R1^ has the identity stated for in Formula IIg, 5 and R2k has the identity stated for R2g in Formula IIg.Identity of LIn one embodiment, L is an amino or substituted amino group of Formula IIi#R1iXR2, (Hi).where R1]. is a monovalent radical, such as a hydrogen atom, a normal or branched, saturated or unsaturated CL-C18-alkoxy group,- a substituted or unsubstituted aryloxv group, a substituted or unsubstituted aryl-CL-C6-alkoxy group, or a substituted or unsubstituted aryloxy-C^-Cgalkoxy or heteroaryl-Ci-Cg-alkoxy group. The aryl group is preferably a phenyl or naphthyl group. The heteroaryl group is a 5- or 6-membered, preferably nitrogen-, oxygenor sulfur- containing, ring system, such as, for example, a heteroaryl group derived from imidazole, isoxazole, isothiazole, thiazole, oxazole, pyrazole, thiophene, furan, pyrrole, 1,2,4- or 1,2,3- triazole, pyrazine, indole, benzofuran, benzothiophene, indole, isoindole, indazole, quinoline, pyridazine, pyrimidine, benzimidazole,-19benzopyran, benzothiazole, oxadiazole,thiadiazole or pyridine. Suitable aryl substituents include one or more halogen, preferably fluorine, bromine or chlorine, atoms, Cx-C4-alkyl groups, methoxy, ethoxy or trifluoromethyl groups, a dioxymethylene group or nitro groups.R2x is a monovalent radical, such as a hydrogen atom, a normal or branched, saturated or unsaturated Cx-Ciaalkyl group, a C3-C10-cycloalkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted heteroaryl group. The aryl group is preferably a phenyl or naphthyl group. The heteroaryl group is a 5- or 6-membered, preferably nitrogen-, oxygen- or sulfurcontaining, ring system, such as, for example, a heteroaryl group derived from imidazole, isoxazole, isothiazole, thiazole, oxazole, pyrazole, thiophene, furan, pyrrole, 1,2,4- or 1,2,3- triazole, pyrazine, indole, benzofuran, benzothiophene, indole, isoindole, indazole, quinoline, pyridazine, pyrimidine, benzimidazole, benzopyran, benzothiazole, oxadiazole,thiadiazole or pyridine.Suitable aryl substituents include one or more halogen, preferably fluorine, bromine or chlorine, atoms,Cx-C4-alkyl groups, methoxy, ethoxy or trifluoromethyl groups, a dioxymethylene group or.nitro groups.R2x can, alternately, be of Formula IIr,-C-(CHj).—R4, (Hr), fR3where ax is an integer, such as 0, 1, 2, 3, 4 or 5. R3L is a monovalent radical, preferably a lower alkyl group, such as a methyl, ethyl, propyl or isopropyl group. R\ is a-19monovalent radical, which can be a saturated or partially unsaturated carbocyclic system comprising from about 3 to about 10 carbon atoms, a substituted or unsubstituted aryl or heteroaryl group, with aryl and heteroaryl and preferred substituents having the meaning stated for R2X in Formula HlR2! can also be a substituent of Formula IIIr,- (CHzJj-W^R5! , wherein Wxis an oxygen or sulfur atom or an K-r\ group.r\ is a monovalent radical, such as a hydrogen atom, a CJ.-C4-alkyl or C3-C7-cycloalkyl group or a substituted or unsubstituted aryl or arylmethyl group, with aryl and its preferred substituents having the meaning stated for R2X from Formula Uj.. r\ is a monovalent radical, preferably a hydrogen atom, a Ci-C^-alkyl group or a C3-C7-cycloaikyl group, a Ci-C^g-alkanoyl group, a benzoyl group or a substituted or unsubstituted aryl or arylmethyl group, with aryl and its preferred substituents having the meaning stated for R2x in Formula IIltr\ can, alternately, be a substituent of Formula IVr, —(CH2)b— Z, (IVr) where bi. is an integer, preferably 2, 3 or 4. Zxcan be a monovalent radical such as a formyl, aminocarbonyl or hydrazinocarbonyl group, or a cyclic or acyclic acetal or thioacetal group.-20R2X can also be a substituent of Formula Vc,OII-(CHJb—>7, (Vr) in which bxhas the above-mentioned meaning. R7X can be a monovalent radical, such as a polyglycol group of the formula -0- (CH2-CH2-0) where dxis an integer, preferably in the range from about 2 to about 4 or from about 40 to about 90.R2X can further be a carbohydrate of Formula VIr,where R0X is a monovalent radical, such as a hydrogen atom, a Cx-C4-alkanoyl or alkyl group, a benzoyl group or a benzyl group.L can also be a β-hydroxylamino group of Formula IIIX, —N / OH•c-CHH2\ (HI,),-21where r\ is a monovalent radical such as a hydrogen atom, a Cj^-Cg-alkyl group or a substituted or unsubstituted aryl group, with aryl and its preferred substituents having the meaning stated for R2].. R10! is a monovalent radical, preferably a hydrogen atom, alkyl, for example, methyl, or a phenyl group.When r and / or s is 1, L can also be an amino group of Formula IV^R2!N—CH H \R4!where R2j. and r\ are each a monovalent radical. R2i and R\ can also be linked by a carbon-carbon bond.Another subclass of compounds of this invention includes peptides of Formula I wherein L is a hydrazido group of Formula VlrH (V,),R11|R12, and R11! is a monovalent radical, preferably a hydrogen atom. R12! can be a monovalent radical such as a hydrogen atom, a normal or branched C^-Cg-alkyl group, a- C3-Cacycloalkyl group, a C3-Ca-cycloalkyl-C1-C4-alkyl group or a substituted or unsubstituted aryl, heteroaryl, aryl-C}.C4-alkyl or heteroaryl-C1-C4-alkyl group, where aryl, heteroaryl and their preferred substituents can be selected from among the options listed for R2]_.1'I' :-22When r and / or s is l, R11]^ can also be selected from among the options listed above for R12lf and the two radicals together can additionally form a propylene or butylene bridge .Another subclass of compounds of this invention includes peptides of Formula X wherein L is a monovalent radical of the formula -0-R13]. or the formula -S-R13]., where R13x is a monovalent radical, such as a C3-Cl0-cycloalkyl group, a normal or branched C2-C16-alkenylmethyl group or a-C16-alkyl group which can be substituted by from 1 to about 5 halogen, preferably fluorine, atoms.R13j_ can also be the radical - (CH2) e-R14!,wliere eisaninteger, preferably 1, 2 or 3. R14x is a monovalent radical, preferably a saturated or partially unsaturated C3-C10-carbocycle.R13! can further be the monvalent radical- [CH2-CH=C (CH3) -CH2]f-H, where f is an integer, preferably 1, 2, 3 or 4.R13! can also be the radical - [CH2-CH2-O]g-CH3, where g is an integer, preferably in the range from 1 to about 5.R13! can also be the radical -(CH2)h-aryl or- {CH2)h-heteroaryl, where aryl and heteroaryl can also be substituted and, along with their preferred substituents, can be selected from the group listed for R2i* h is an integer, preferably 0, 1, 2 or 3.R13x can further be the radical - (CH2)1}-W1tR51 . b, Wxand r\ can each be selected from among the options described for Formula IVX.Another subclass of compounds of this invention includes peptides of Formula I in which L is an aminoxy group of the formula -O-NfR15].) CR1GL) , where R15]^ and R16x are each a monovalent radical, which can independently be a-23hydrogen atom, a normal or branched C^-Cg-alkyl group, which can be substituted by halogen, preferably fluorine, atoms, a C3-C0-cycloalkyl group, a C3-C0-cycloalkyl• C1-C4-alkyl group, a substituted or unsubstituted aryl or 5 heteroaryl group or a substituted or unsubstituted aryl-C!-C4-alkyl group. Aryl and heteroaryl groups and the preferred substituents thereof can be selected from the options listed for R2!, R16x can be selected from among the options listed for R15x. Additionally, R15x and R16x can together form a 5-, 6- or 7-membered heterocycle. The compounds of the present invention further comprise the salts of the compounds described above with physiologically tolerated acids .Another subclass of compounds of this invention includes peptides of Formula X wherein L is an oximato group of the formula -O-N=C(R151) (R1SX) , R153 and Rlfix can be selected from among the options listed above and, additionally, can together form a cyclic system comprising, preferably, from about 3 to about 7 ring atoms. This cyclic system can additionally be fused to one or more aromatic rings. Particularly preferred cyclic systems are shown below.In one embodiment, the invention provides compounds of Formula I wherein A is an amino acid derivative selected from among N-alkyl-D-prolyl, N-alkyl-L-prolyl, N-alkyl-D- ί piperidine-2-carbonyl, N-alkyl-L-piperidine-2-carbonyl,N, N-dialkyl-D-2-ethyl-2-phenylglycyl and N,N-dialkyl-L-2- j !ethyl-2-phenylglycyl, wherein alkyl is methyl, ethyl or |I isopropyl; and B is a valyl, isoleucyl or 2-t-butyl-Lglycyl residue.Bav-3 2-25Preferred compounds of the invention include compounds of Formula I wherein r and s are each 0. A is an amino acid derivative selected from amongD-N-methyl-piperidine-2-carbonyl,5. L-N-methyl-piperidine-2-carbonyl, N,N-dimethylaminoisobutyryl, N-methyl-L-prolyl,N-methyl-L-thiazolidine-4-carbonyl, N,N-dimethylglycyl, L-prolyl, L-piperidine-2-carbonyl,N-propyl-D-piperidine-2-carbonyl,D-piperidine-2-carbonyl, N-ethyl-D-piperidine-2-carbonyl, N-methyl-[2,2,5,5-tetramethyl]-L-thiazolidine-2-carbonyl,N-isopropyl-D-piperidine-2-carbonyl, N,N-dimethyl- 2 cyclopropylglycyl, N, N-dimethyl-L-2-ethyl-2-phenylglycyl,N,N-dimethyl-D-2-ethyl-2-phenylglycyl, D-prolyl,N-methyl-D-prolyl, N,N-dimethyl-2-(2-f luorophenyl) glycyl,1- aza-[3,3,0]bicyclooctyl-5-carbonyl,N,N-dimethyl-2- [4-fluoro] phenyl-glycyl,N-methyl-[2,2,5,5-tetramethyl]-thiazolidine-2-carbonyl,- (R, S) - ethyl - 2 - phenylglycyl, D,L-1- amino indane -1 - carbonyl,N, N-dimethyl-2 - (R, S)-methyl-2-phenylglycyl,2- [N,N-dimethylamino]indane-2-carbonyl,5-[N,N-dimethylamino]-5,6,7,8-tetrahydronaphthalene -5 -carbonyl, N-isopropyl-2- (R,S)-ethyl-2phenylglycyl, 1- [N, N-dimethyl ami no] indane-2 -carbonyl,N,N-dimethyl-2-propyl-2-phenylglycyl,N, N-dimethyl-2 - [4-methoxy] phenyl-glycyl,N-methyl-3-hydroxy-D, L-valyl, N, N-dimethyl-D,L-2- isopropyl2-phenylglycyl, N-methylpiperidine-2-carbonyl,N-methyl-L-prolyl, N-methyl-1,2,3,43 0 tetrahydroisoquinoline-1-carbonyl,-26N-methylazetidine-2-carbonyl, N-isopropylazetidine2-carbonyl, Ν,Ν-dimethyl-[O-methyl]seryl,Ν,Ν-dimethyl-[O-methyl]threonyl,N-methyl-1,2,3,4-tetrahydroisoguinoline-3-carbonyl,1-[Ν,Ν-dimethylamino]cyclohexyl-1-carbonyl,1- [Ν,Ν-dimethylamino]cyclopentyl-1-carbonyl and1,2,3,4-tetrahydroisoquinoline-3-carbonyl. B is valyl, isoleucyl or 2-tert-butylglycyl. D is N-methylvalyl, Nmethyl-2-t-butylglycyl or N-methylisoleucyl. E and F are each, independently, prolyl, thiaprolyl, homoprolyl, hydroxyprolyl, 3,4-didehydroprolyl, 4-fluoroprolyl, and 3methylprolyl. L is an alkoxy group or an amino group of the formula R^-N-R2^ wherein r\ and R2X are independently selected from the group consisting of hydrogen, alkoxy, hydroxy, alkyl and alkylaryl.In a particularly preferred subset of the compounds of the invention, r and s are each 0. A is an amino acid derivative selected from amongD-N-methyl-piperidine-2-carbonyl, N-ethyl-D-piperidine2- carbonyl, N-isopropyl-D-piperidine-2-carbonyl,N,N-dimethyl-2-cyclopropyl-glycyl, N-methyl-D-prolyl,1- aza-[3,3,0]bicyclooctyl-5-carbonyl,N-methyl-[2,2,5,5-tetramethyl]-thiazolidine-2-carbonyl,2- {R,S)-ethyl-2-phenylglycyl, D, L-l-aminoindane-1-carbonyl, N,N-dimethyl-2-(R,S)-methyl-2-phenylglycyl,5-[Ν,Ν-dimethylamino]-5,6,7,8-tetrahydronaphthalene -5 -carbonyl ,1- [Ν,Ν-dimethylamino]indane-2-carbonyl,N, N-dimethyl - 2 -propyl-2-phenylglycyl ,· N, N-dimethyl-L2- ethyl-2-phenylglycyl, N,N-dimethyl-D2-ethyl-2-phenylglycyl, N-methyl- 3 - hydroxy-D, L- valyl,N, N-dimethyl-D, L-2-isopropyl-2-phenylglycyl,-27N-methyl-piperidine-2-carbonyl, N-methyl-D,L-prolyl, N-methyl-1,2,3,4-tetrahydroisoquinoline-l-carbonyl, N-methylazetidine-2-carbonyl,N-isopropylazetidine-2-carbonyl,Ν,Ν-dimethyl-[0-methyl]seryl,1-[Ν,Ν-dimethylamino]cyclohexyl-l-carbonyl and1-[Ν,Ν-dimethylamino]cyclopentyl-l-carbonyl. B is valyl; D is N-methylvalyl; and E and F are each prolyl. L is a CiCg-alkoxy group or an amino group of the formula R^-N-R2!, wherein r\ and R2X are each independently selected from the group consisting of hydrogen, Ci-Cg-alkoxy, hydroxy, normal, cyclic or branched C1-C12-alkyl, and phenylalkyl.Synthetic Methods 'The compounds of the present invention can be prepared by known methods of peptide synthesis. Thus, the peptides can be assembled sequentially from individual amino acids or by linking suitable small peptide fragments. In sequential assembly, the peptide chain is extended stepwise, starting at the C-terminus, by one amino acid per step. In fragment coupling, fragments of different lengths can be linked together, and the fragments in turn can be obtained by sequential assembly from amino acids or by fragment coupling of still shorter peptides.In both sequential assembly and fragment coupling it is necessary to link the units by forming an amide linkage, which can be accomplished via a variety of enzymatic and chemical methods. Chemical methods for forming the amide linkage are described in detail in standard references on peptide chemistry, including Muller, Methoden der organisghSILChemie Vol. XV / 2, 1-3G4, Thieme Verlag, Stuttgart, (1974); Stewart and Young, Solid Phase Peptide-28Synthesis, 31-34 and 71-82, Pierce Chemical Company, Rockford, IL (1984); Bodanszky et al., Peptide Synthesis, 85-128, John Wiley & Sons, New York, (1976) . Preferred methods include the azide method, the symmetric and mixed anhydride method, the use of in situ generated or preformed active esters, the use of urethane protected N-carboxy anhydrides of amino acids and the formation of the amide linkage using coupling reagents, such as carboxylic acid activators, especially dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), l-ethoxycarbonyl-2ethoxy-1,2-dihydroquinoline (EEDQ), pivaloyl chloride, l-ethyl-3- (3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), n-propanephosphonic anhydride (PPA), Ν,Ν-bis(2-oxo-oxazolidinyl)amidophosphoryl chloride (BOP-CI), bromo-tris(pyrrolidino)phosphonium hexafluorophosphate (PyBrop), diphenylphosphoryl azide (DPPA), Castro's reagent (BOP, PyBop),O-benzotriazolyl-N,N,Ν',Ν'-tetramethyluronium salts (HBTU) , O-azabenzotriazolyl-N,N,Ν',N‘-tetramethyluronium salts (HATU) , diethylphosphoryl cyanide (DEPCN) ,2,5-diphenyl-2,3-.dihydro-3-oxo-4- hydroxythiophene dioxide (Steglich’s reagent; HOTDO) , and 1,1’-carbonyldiimidazole (CDI) . The coupling reagents can be employed alone or in combination with additives such asN,N-dimethyl-4-aminopyridine (DMAP), N-hydroxybenzotriazole (HOBt), N-hydroxyazabenzotriazole (HOAt), N-hydroxybenzotriazine (HOOBt) , N-hydroxysuccinimide (HOSu) or 2-hydroxypyridine.Although the use of protecting groups is generally not necessary in enzymatic peptide synthesis, reversible protection of reactive groups not involved in formation of the amide linkage is necessary for both reactants in-29chemical synthesis. Three conventional protective group techniques are preferred for chemical peptide synthesis: the benzyloxycarbonyl (2), the t-butoxycarbonyl (Boc) and the 9-fluorenylmethoxycarbonyl (Fmoc) techniques.Identified in each case is the protective group on the α-amino group of the chain-extending unit, A detailed review of amino-acid protective groups is given by Muller, Methoden der orcranischen Chemie Vol. XV / 1, pp 20-906,Thieme Verlag, Stuttgart (1974). The units employed for assembling the peptide chain can be reacted in solution, in suspension or by a method similar to that described by Merrifield, J. Am. Chem. Soc. 85: (1963) 2149.Solvents suitable for peptide synthesis include any solvent which is inert under the reaction conditions, especially water, N,N-dimethylformamide (DMF), dimethyl sulfoxide (DMSO), acetonitrile, dichloromethane (DCM), 1,4-dioxane, tetrahydrofuran (THF), N-methyl-2-pyrrolidone (NMP) and mixtures of these solvents.Peptide synthesis on the polymeric support can be carried out in a suitable inert organic solvent in which the amino acid derivatives starting materials are soluble. However, preferred solvents additionally have resinswelling properties, such as DMF, DCM, NMP, acetonitrile and DMSO, and mixtures of these solvents. Following synthesis, the peptide is removed from the polymeric support. The conditions under which this cleavage is accomplished for various resin types are disclosed in the literature. The cleavage reactions most commonly used are acid- or palladium-catalyzed, the former being conducted in, for example, liquid anhydrous hydrogen fluoride, anhydrous trifluoromethanesulfonic acid, dilute or concentrated trifluoroacetic acid, and acetic acid / -30dichloromethane / trifluoroethanol mixtures. The latter can be carried out in THF or THF-DCM-mixtures in the presence of a weak base, such as morpholine. Certain protecting groups are also cleaved off under these conditions.Partial deprotection of the peptide may also be necessary prior to certain derivatization reactions. For example, peptides dialkylated at the N-terminus can be prepared by coupling the appropriate N,N-di- alkylamino acid to the peptide in solution or on the polymeric support, by reductive alkylation of the resin-bound peptide in DMF / lY acetic acid with NaCNBH3and the appropriate aldehyde or by hydrogenation of the peptide in solution in the presence of the appropriate aldehyde or ketone and Pd / carbon.The various non-naturally occurring amino acids as well as the various non-amino acid moieties disclosed herein can be obtained from commercial sources or synthesized from commercially available staring materials using methods known in the art. For example, amino acid building blocks with R1and R2groups can be prepared according to the method described by Wuensch and Weyl, Methoden der Organische Chemie. vol. XV, Springer Verlag: Stuttgart, p. 306 (1974) and references cited therein.Methods of Use of the Claimed CompoundsIn another embodiment, the present invention comprises a method for partially or totally inhibiting formation of, or otherwise treating (e.g., reversing or inhibiting the further development of) solid tumors (e.g., tumors of the lung, breast, colon, prostate, bladder, rectum, or endometrial tumors) or hematological malignancies (e.g., leukemias, lymphomas) in a mammal, for example, a human, by-31administering to the mammal a therapeutically effective amount of a compound or a combination of compounds of Formula I. The compound(s) may be administered alone or in a pharmaceutical composition comprising the compound(s) and an acceptable carrier or diluent. Administration can be by any of the means which are conventional for pharmaceutical, preferably oncological, agents, including oral and parenteral means, such as subcutaneously, intravenously, intramuscularly and intraperitoneally, nasally or rectally. The compounds may be administered alone or in the form of pharmaceutical compositions containing a compound or compounds of Formula I together with a pharmaceutically accepted carrier appropriate for the desired route of administration. Such pharmaceutical compositions may be combination products, i.e., they may also contain other therapeutically active ingredients.The dosage to be administered to the mammal, such as a human, will contain a therapeutically effective amount of a compound described herein. As used herein, therapeutically effective amount is an amount sufficient to inhibit (partially or totally) formation of a tumor or a hematological malignancy or to reverse development of a solid tumor or other malignancy or prevent or reduce its further progression. For a particular condition or method of treatment, the dosage is determined empirically, using known methods, and will depend upon factors such as the biological activity of the particular compound employed; the means of administration; the age, health and body weight of the recipient; the nature and extent of the symptoms; the frequency of treatment; the administration of other therapies; and the effect desired. A typical daily dose will be from about 0.05 to about 50 milligrams per-32kilogram of body weight by oral administration and from about 0.01 to about 20 milligrams per kilogram of body weight by parenteral administration.The compounds of the present invention can be S administered in conventional solid or liquid pharmaceutical administration forms, for example, uncoated or (film-)coated tablets, capsules, powders, granules, suppositories or solutions. These are produced in a conventional manner. The active substances can for this purpose be processed with conventional pharmaceutical aids such as tablet binders, fillers, preservatives, tablet disintegrants, flow regulators, plasticizers, wetting agents, dispersants, emulsifiers, solvents, sustained release compositions, antioxidants and / or propellant gases (cf. H. Slicker et al. : Pharmazeutische Technologie.Thieme-Verlag, Stuttgart, 197Θ). The administration forms obtained in this way typically contain from about 1 to about 90% by weight of the active substance.The present invention will now be illustrated by the following examples, which are not limiting.L·'EXAMPLESThe proteinogenous amino acids are abbreviated in the examples using the known three-letter code. Other abbreviations employed are: TFA - trifluoroacetic acid, Ac a acetic acid, DCM - dichloromethane, DMSO dimethylsulfoxide, Bu = butyl, Et = ethyl, Me = methyl, Bzl = benzyl. In the compounds listed, all proteinogenous amino acids are L-amino acids unless otherwise noted.Other abbreviations used: Me2Val =* N,N-dimethylvaline,MeVal « N-methylvaline, Bn = benzyl, Me2Aib [2-N,N-dimethylamino]-isobutyric acid.General ProceduresThe peptides of the invention are synthesized either by classical solution synthesis using standard Z- and Boc-methodology as described above or by standard methods of solid-phase synthesis using Boc and Fmoc protective group techniques.In the case of solid phase synthesis, the Ν,Ν-dialkyl-penta- or hexapeptide acids are liberated from the solid support and further coupled with the corresponding C-terminal amines in solution.. BOP-Cl and PyBrop were used as reagents for coupling of the amino acid following the N-methylamino acids. The reaction times were correspondingly increased. For reductive alkylation of the N-terminus, the peptide-resin was deprotected at the N terminus and then reacted with a 3-fold molar excess of aldehyde or ketone in DMF / 1% acetic acid with addition of 3 equivalents of NaCNBH3. After the reaction was complete (negative Kaiser test) the resin was washed several times with water, isopropanol, DMF and dichloromethane.-34In solution synthesis, the use of either Boc-protected amino acid NCAs (N-tert.-butyloxycarbonyl-amino acid-N-carboxy-anhydrides}, Z-protected amino acid NCAs (N-benzyloxycarbonyl-amino acid-N-carboxy-anhydrides) , or the use of pivaloyl chloride as condensing agent' respectively is most advantageous for coupling of the amino acid following the N-methylamino acids. Reductive alkylation of the N terminus can e.g. be achieved by reaction of the N-terminally deprotected peptides or amino acids with the corresponding aldehydes or ketones using NaCNBH3or hydrogen-Pd / C.Valyl -N-methylvalyl -prolyl -prolylbenzylamide hydrochloride for example was prepared according to methods disclosed in German Patent Application No. DE 19527575 Al.Purification and characterization of the peptidesPeptide purification was carried out by gel chromatography (SEPHADEX G-10, G-15 / 10% KOAc, SEPHADEX LH20 / MeOH)< medium pressure chromatography (stationary phase: HD-SIL C-18, 20-45 micron, 100 Angstrom; mobile phase: gradient with A = 0.1% TFA / MeOH, B = 0.1% TFA / water), preparative HPLC (stationary phase: Waters Delta-Pak C-18, 15 micron, 100 Angstrom; mobile phase: gradient with A - 0.1 % TFA / MeOH, B 0.1 % TFA / water) , or by crystallization.The purity of the resulting products was * determined by analytical HPLC (stationary phase: 100 2.1 mm VYDAC C-18, 5 micron, 300 A; mobile phase: acetonitrile-water gradient, buffered with 0.1% TFA, 40°C; or 3.9 mm VYDAC C-18, 30°C). Characterization was by fast atom bombardment mass spectroscopy and NMR-spectroscopy.Example 1 Synthesis of [N-Methyl-L-piperidine-2-carbonyl]-Val-MeVal -Pro-Pro-NHBn (Compound 1) and [N-Methyl-D-piperidine-2-carbonyl]-Val-MeVal -Pro-Pro-NHBn (Compound 2)Preparation of N-methyl-piperidine-2-carboxylic acidN-Methyl-piperidine-2-carboxylic acid ethyl ester (5.1g) was dissolved in a mixture of 100 ml methanol and 10 ml water. NaOH (8 g) was added and the reaction^mixture was stirred at room temperature overnight. The solution was then neutralized with hydrochloric acid, evaporated to dryness, and evaporated four times with toluene. The ·. resulting powdery residue was used directly in the next step.Preparation of [N-Methyl-piperidine-2-carbonyl]-Val-MeVal-Pro-Pro-NHBnThe residue prepared as described above (5.05 g) andH-Val-MeVal-Pro-Pro-NHBn x HCI (4.88 g) were dissolved in 50 ml dry DMF. After cooling the solution in an ice bath, 1.52 g DEPCN and 2.66 ml triethylamine were added. The reaction mixture was stirred at 0°C for 2 h and then at room temperature overnight. The DMF was removed by evaporation under reduced pressure. The residue was diluted with dichloromethane and the organic phase was washed with aqueous hydrochloric acid (pH 2) and water, dried over sodium sulfate and evaporated to dryness. The diastereomeric mixture was then separated by flash chromatography with a gradient using heptane / ethyl acetate and dichloromethane / methanol. Under the HPLC conditions-36described in the previous section (C-18 reverse phase) isomer 1 has a retention time of 14.9 minutes, and isomer 2 has a retention time of 15.8 minutes. Both isomers were characterized by fast atom bombardment mass spectrometry ( [M+H] + =« 639) .Example 2 Preparation of Me2Aib-Val-MeVal-Pro-Pro-NHBn {Compound 3)Preparation of 2-[Ν,Ν-dimethylamino]-isobutyric acid2-Amino-isobutyric acid (10.3 g) was dissolved in 200 ml methanol. After addition of 25 ml aqueous formaldehyde and 1 g 10% Pd / C, the reaction mixture was hydrogenated overnight at room temperature. The catalyst was filtered, and the filtrate was evaporated to dryness. The residue was crystallized from isopropanol to give 4.8 g of the desired product.Preparation of Me2Aib-Val-MeVal-Pro-Pro-NHBn x HCI2-[N, N-Dimethylamino]-isobutyric acid (1.3 g, 10 mmol) and 5.5 g (10 mmol) H-Val-MeVal-Pro-Pro-NHBn x HCI were dissolved in 50 ml dry DMF. After cooling to 0°C, 1.6 g DEPCN (10 mmol) and 2.9 ml triethylamine were added to the reaction mixture. The resulting mixture was stirred at 0eC for 2 h and at room temperature overnight. Ice-water (50 mL) was then added, and the resulting mixture was extracted twice with diethyl ether. The ether extracts were washed with 1 N NaOH (lx) and aqueous NaCl (3x) , then dried over sodium sulfate and evaporated to dryness under reduced pressure. The product was crystallized from 100 ml diethyl ether with HCl / ether, and recrystallized from acetone to give 1.2 g of the desired product, which was characterized by fast atom bombardment mass spectrometry ( [M+H] + = 627).• · · · · · · · »t · · • · · · * · · · · · • · · · · » » · · · » » t» • · · · · · · ·« • · « · « · • · · · · · • · · · · · • · · « · · • · · · ·« «· · sqx ’jtsqEM puie ' (OT-6 Hd) HO©N snosnbE sqnxTp 'jsqEM ' (Z Hd) TOH snosnbB sqnjTp qqxM psqsEM Xxqbno^oqq puE sqEqsoE-[Xqqs qqTM psqnxTp sem snpTss.x sqx -sanssEJd psonpsj ^spun pEqEJtodEAE sem awa ©q^ usqq 'qqfiTUZBAO sznqEJsduisq uiooj pine sznoq tejisass joj οβο ZE ps^z-cqs sem s.znqxTui uoTqoES.1 sqx S3 -psppE sjsm (-[ouiui OC) ©UTUJE-[XqqETzq jui pine {journi ST 'Tui S3 *3) N0d3Q & t’Z 'De0 oq Buttooo ^sqjv *3Wa Azp χιη 00 ui ρΕΛχοεετρ sjsm (touiui ST) -[oh x UHHN-o.id-o.id-T©A©W-T©A-H β S3’0 ptne (W3H0VH 'touiui ST) HO-o^d-d-Z & Wt uaHN-O-id-o^d-T^AeW-T^A-O-ia-a-Z ?o uoxqEJEdEJd 03 (S punodmoo) ugHN-o^d-O-id-T^ASW-T^A- [O-Xd-d-T^H^W-N] jo uoxqEJEdsjd STduiEXH • (COZ. = + tH+W] )Axqsuiojqosds sseui qusuip.ZBqmoq rnoqE qsEj Xq pszTjsqoEJEqo st sem qozqM 'qonpojd psjTSsp.sqq jo 6 t sat5 oq Jsqqs / TOH .qqTM jsqqs TXqqszp uiojj pszTTTBqsXro sem qonpo-id spruo sqj, •SAoqE psq-pjossp se dn psq.xoM usqq 'qqBTiixSAO sjnqE^sduisq uiooj: qE pine q z -ioj OeO psxiTqs sem s^nqxTm uoTqoESj:sqx *psppE sjtsm EUTUiBTXqqsT.iq Tm6 * Z ptne (xomm QT) N0d3d 0T B 9‘T '0.0 oq βιιττοοο jsqjv *3Wd Λζρ χιιι 00T ui psATOssypSJBM TOH x UHHN-o;td-o.xa-TEA3W-T©A-H (Touiui oi) 5 S*S pUBEUToXT6TXusqd-£--[Xqqs-£--[XqqsmTa-,N'ij (xomm oi) β LQ'ZTOH x ^hHN-ojd-oJd-T^ASW-T^A- [T^oXTST^UBqd-j-xXqqs-z-xXqqsuiTp-K'N] S jo uoTqE.iBds.Zd (fr punodmoo) TOH x u0HN-o.Zd-oxd-T©A ©W-Τ^Λ- [T^oXTSptosqd-z-P^P©-3- ptqqsuiTp-N 'N] jo uoTqE^EdBJdC BxduiExa-Δ3• · I • · · · · · • · * · · · · • · ··· ··· • · · · * · • · * · * · • · · · ·· ··· • · • 9 • · • · • · ) · · · · · · • · · · 4 • · · · 4 • · · · · · aqq 30 β s*0 θλτ£ oq qpes apyaoyqooapAq aqq se pazyyyeqsAiio oe sew anpysaq aqx -ssauAxp oq peqeaodeAa pue aqejyns uinypos mo payap eaeA sqoeqqxa oyuefiao aqx aueqqauioaoyxpyp qqyA aojMq paqoerqxa pue OT-6 H<3 oq paqsnCpe sbm aseqd snoanbe aqx · axieqqauioaoyqoyp qqyA sauiyq yeuoyqyppe yeqaAas pue aaipa yAqqayp qqyA aoyAq paqoeqqxa pue sz Z Hd oq paqsnCpe 'aaqew uy paAyossyp sew anpysaa 5uyq-[n£3i aqq 'squaAyos aqq 30 uoyqeqodeAa pue uoyqeqqyy3 buyAoyyoj *paqeua£ozpAq sew arnqxyui uoyqoeai aqq pue uoyqnyos apAqapyeuLxo3 snoanbe yui s*y pue yeooaeip / pa JfcOT £ C'O P®PP* uaqq sew uoyqnyos syqq οχ -youeqqaui yin oe uy paAyossyp sbm qz yoH x uaHN-ora-ora-xeAsw-i^A-ora-a 30 (youiui ο & ^6*τ tdh x uaHN-oza-o«id-T«A»W-T«A-[OJa-a-TAqqsm-N] 30 uoyqeredaja *qonpo.xd parysap aqq 30 & S’9 3λτ£ oq qyes apyqoyqooapAq aqq se zeqqe / TDH 3° uoyqyppe Aq pazyyyeqsAiio pue ST qaqqayAqqayp uy paAyossypaa sew anpysar eqq pue paqerodeAa 9Ι3Λ sqoerqxa oyxiebro aqx · aueqqauioqoyqoyp qqyM aoy^q paqoerqxa pue 0T-6 H<3 oq paqsnCpe sew aseqd snoanbe aqx •aqeqaoe yAqqa qqyA aoyAq paqoerqxa pue z H<3 oq paqsnCpe 'xeqew uy paAyossyp sew qoyqA anpysar e aAe£ quaAyos OT aqq 30 uoyqexodeAa pue uoyqexqyyj -paqeua£orpAq sew axnqxyui Buyqynsaa aqq 'uoyqnyos aqq oq yeooaeqo / uinypeyyed % OT £ Γ0 pue pyoe oyxoyqoorpAq paqezquaouoo yui fo 30 uoyqyppe xeqyv · youeqqaui yui ot uy paAyossyp seA usHN-o.xa-o;ra~T®A3W-T*A-o.xa-a-Z (TOUIU1 n) £ ΓΘ 5TOH X uaHN-oxa-oaa-T^A^W-T^A-oxa-a 30 uoyqeredard •apyqdadequad paqoaqoxd paxysap aqq 30 £ z' 6 pysyA oq ssauA^p oq paqerodeAa pue aqe3yns uinypos mo payqp seA aseqd oyueBxo-ee• · ·· ··· ·· ♦ · · ♦ * · · · · ·· «· *· • ··· ·>· · · · » · · · · · • · * · · · » · · · · · ·q*X q*x φεχ o^d eex ΧΒΛ oqx o;ta Bex jeA qqx 63 B3 LZ Ξε o;ta eex Τ*Λ Bqx z it SUIOST q*x oita eex t*a zex 93 τ -Z3WOSX q*x oita eex Τ*Λ zex S3 qex OJd eex ΤΒΛ Zex fr3 z JSU1OSX q*x oita eex τ*λ xex £3 οε τ JSU1OSX q«X oita eex τ*λ XBX 33 q*x 0.1a eex τ*λ 6ex τζ q«X 0.1a eex ΤΒΛ Aex 03 q*x oaa eex τ*Λ ?BX 6T z aernosx q*x oitd eex ΤΒΛ 3BX 8T S3 τ it SUIOST q«X oaa eex Τ*Λ ϋΒΧ LT q^X oita eex τ*λ sex 9T q«X oaa eex ΤΒΛ itex ST q«X oaa eex Τ*Λ bex ^T dex oaa eex ΤΒΛ pex ετ 03 q«X oaa eex τ*λ oex 3T xqx oaa eex ®τι wex IT q*x oaa eex τ*λ uiex OT -xqx oita eex τ*Λ PBX 6 q*x oaa eex τβδ eex 8 ST q*x 0.1a eex τ*λ xex L qsx oaa eex Τ*Λ qex 9•ON punoduioo τ οτ • ζUT pspTAoad site spunoduioo peqoeqes joj sq^nseit Zitqeuioitqoeds sseui-queuipitequioq uioqe qsea -uieqsZs oqaH TBOTqZqeue eseqd pesiteASit eqq uo eurcq uoyqueqeit iteqitoqs eqq qqxrt iteuioeiteqseTp eqq sx τ iteuiosx \Z asuiosx,, jo „τ asuiosxMse oq psitjejeit site spunoduioo s θ,ζθμΜ ’V-τ seqdmexa ut psqxaosep spoqqeui eqq oq Buxpitoooe peitedeitd sjsm χ e-fqej,UT psqsxx spunoduioo eqx ‘ (S39 + [H+W] ) Zzqeuioitqoeds sseui queuipitequioq uioqe qseg Zq pezTiteqoeiteqo sew qoxqw qonpoitd psjxssp-6ε·· • · · • · · • · · • · · • · ·· · ··· * · · • · · « · • · · • · · • · ♦ • · · ···· ··«· • · · • · · • · · «· ·· ···· • ·II β ·· • · · · • · « • * · • · · • β·· ·· ·· ·· • · • ··· ·· * · • · · ·· · ·xqx o^a **x Ϊ*Λ ΛΒΧ 99 ot ε JSUIOST bqx oaa Τ«Δ oqx 59 τ JSUIOST Sqx o^a **X τ*Λ oqx t9 ε aaujosT zqx ojia ««X τ*λ oqx C9 τ J3U1OST xcix o^a V*X τ*Λ oqx 29 ε iSUJOST q*X o^a ενχ τ*Λ nqx 19 sc ε jiamosT 3QX o^a ετ?χ τ*Λ sqx 09 ε JSUIOST q*X oaa ΈΪΧ Ϊ*Λ «qx 65 τ JSUIOST q*X oaa ΈΈ?Χ τ*Λ *qx BS q*X o^a ΈΒΧ τ*Λ Aqx £5 τ jtsujost q*x oaa ΈΒΧ τ*λ nqx 95 oc ε JSUIOST q*X oaa ««X τ*λ iqx 55 τ JSUIOST q*x oaa ««X τ*λ iqx tS τ aaiuosT 3qx oja ««X τ*λ sqx CS jqx oaa τ*λ ΛΒΧ zs bqx oaa ««X τ*Λ Λ*Χ TS S3 ε jeuiosT oqx ojia ΒΪΧ τ*λ oqx 05 τ jrSUlOST Sqx oaa ««X τ*λ oqx 6t <3ςχ oaa ««X τ*λ ΛΪΧ 8t ε JX3WOST uqx ojia ««X τ*λ oqx Ll· τ JSUiOST uqx oaa **Χ τ*λ oqx 9t 03 uqx o^a ΪΪΧ τ*λ ΛΪΧ St q*X caa ΪΒΧ τ*λ wqx ft ε jxawosT q*X oja **Χ τ*λ ?qx ct q*X oaa ««X τ*λ iqx Zl· ε aewos7 q^X caa **Χ τ*λ ^qx Tl· ST τ asuiosT qex oaa ΡΒΧ τ*λ sfqx Ot ε JSUIOST q^X ooa ««X ΤΒΛ pqx 6C τ JSUIOST q^x o;ia ««X τ*λ TQX 8C ε JSUIOST q*X ooa **Χ τ*Λ qqx LZ τ JZSUIOST q*X ooa **Χ τ*λ qqx 9C 0T q*X oza ρ^χ τ*λ £qx SC τ .zeuiosT q*X o;ia **Χ τ*λ gqx te ε JSUiOST q*X ooa *Έ?Χ τ*λ eqx CC τ JBUIOST qrx ooa ΈΪΒΧ τ*λ eqx zz ε iBUlOST q^X ooa ΒΒΧ τ*Λ pqx TC s τ J3WO5J q*X ooa ΒΈ?Χ τ*λ pqx oc•ΟΝ punoduioo Τ ξ>ΙΦ?1-ot41Table 1 CompoundNo.67 Xby Val Xaa Pro Xab 66 Xbz Val Xaa Pro Xab 69 Xca Val Xaa Pro Xab isomer 1 70 Xca Val Xaa Pro Xab isomer 2 71 Xbo Val Xaa Pro Xbx isomer 1 72 Xbo Val Xaa Pro Xbx isomer 2 73 Xau Val Xaa Pro Xbp 74 Xau Val Xaa Pro Xbx 75 Xbi Val Xaa Pro Xbx isomer 2 76 Xau Val Xaa Pro Xab isomer 1 77 Xau Val Xaa Pro Xab isomer 2 76 Xau Val Xaa Pro Xcb 79 Xbi Val Xaa Pro Xcb isomer 1 80 Xbi Val Xaa Pro Xcb isomer 2 81 Xbi Val Xaa Pro Xcc isomer 1 82 Xbi Val Xaa Pro Xcc isomer 2 83 Xbi Val Xaa Pro Xcd 84 Xbk Val Xaa Pro Xcc isomer 1 85 Xbk Val Xaa Pro Xcc isomer 2 86 Xax Val Xaa Pro Xbp isomer 1 87 Xax Val Xaa Pro Xbp isomer 2 sa Xbk Val Xaa Pro Xcb isomer 1 89 Xbk Val Xaa Pro Xcb isomer 2 90 Xau Val Xaa Pro Xcc 91 Xau Val Xaa Pro Xcd 92 Xba Val Xaa Pro Xcb isomer 1 93 Xba Val Xaa Pro Xcb isomer 2 94 Xbo Val Xaa Pro Xbp isomer 1 95 Xbo Val Xaa Pro Xbp isomer 2 96 Xau Val Xaa Pro Xbp isomer 1 97 Xau Val Xaa Pro Xbp isomer 2 98 Xbi Val Xaa Pro Xcd isomer 2 99 Xbk Val Xaa Pro Xcd 100 Xba Val Xaa Pro Xbp isomer 1 101 Xba Val Xaa Pro Xbp isomer 2 102 Xba Val Xaa Pro Xcc isomer 1* 25Table 1 CompoundNo.103 Xba Val Xaa Pro Xcc 104 Xba Val Xaa Pro Xcd 105 Xce Val Xaa Pro Xab 105 Xcf Val Xaa Pro Xab 107 Xcg Val Xaa Pro Xab 108 Xcg Val Xaa Pro Xab 109 Xaw Val Xaa Pro Xch 110 Xaw Val Xaa Pro Xci 111 Xaw Val Xaa Pro Xck 112 Xaw Val Xaa Pro Xcl 113 Xaw Val Xaa Pro Xcm 114 Xaw Val Xaa Pro Xcn 115 Xaw Val Xaa Pro Xco 115 Xaw Val Xaa Pro Xcp 117 Xaw Val Xaa Pro Xcq 118 Xaw Val Xaa Pro Xcr 119 Xad Val Xaa Pro Xch 120 Xad Val Xaa Pro Xci 121 Xad Val Xaa Pro Xck 122 Xad Val Xaa Pro Xcl 123 Xad Val Xaa Pro Xcm 124 Xad Val Xaa Pro Xcn 125 Xad Val Xaa Pro Xco 125 Xad Val Xaa Pro Xcp 127 Xad Val Xaa Pro Xcq 128 Xad Val Xaa Pro Xcr 129 Xad Val Xaa Pro Xbx 130 Xau Val Xaa Pro Xch 131 Xau Val Xaa Pro Xci 132 Xau Val Xaa Pro Xck 133 Xau Val Xaa Pro Xcl 13 4 Xau Val Xaa Pro Xcm 135 Xau Val Xaa Pro Xcn 135 Xau Val Xaa Pro Xco 137 Xau Val Xaa Pro Xcp 138 Xau Val Xaa Pro Xcq 139 Xau Val Xaa Pro Xcrisomer 2 isomer 1 isomer 2-43Table 1 CompoundNo.140 Xau Val Xaa Pro Xbr 5 141 Xad Val Xaa Xal Xbx 142 Xau Val Xaa Xal Xbx 143 Xaw Val Xaa Xal Xbx 144 Xad Val Xaa Xal Xch 145 Xau Val Xaa Xal Xch 10 14S Xaw Val Xaa Xal Xch 147 Xad Val Xaa Xal Xcr 148 Xau Val· Xaa Xal Xcr 149 Xaw Val Xaa Xal Xcr 150 Xad Val Xaa Xan Xbx 15 151 Xau Val Xaa Xan Xbx 152 Xaw Val Xaa Xan Xbx 153 Xad Val Xaa Xan Xch 154 Xau Val Xaa Xan Xch 155 Xaw Val Xaa Xan Xch 20 15S Xad Val Xaa Xan Xcr 157 Xau Val Xaa Xan Xcr 158 Xaw Val Xaa Xan Xcr 15 9 Xau lie Xaa Pro Xbx ISO Xad He Xaa Pro Xbx 25 161 Xaw lie Xaa Pro Xch 162 Xad lie Xaa Pro Xch 163 Xau He Xaa Pro Xch 164 Xaw Xcs Xaa Pro Xch 165 Xad Xcs Xaa Pro Xch 30 166 Xau Xcs Xaa Pro Xch 167 Xaw Xcs Xaa Pro Xbx 168 Xad Xcs Xaa Pro Xbx 169 Xau Xcs Xaa Pro Xbx 170 Xaw Val Xct Pro Xch 35 171 Xad Val Xct Pro Xch 172 Xau Val Xct Pro Xch 173 Xaw Val Xct Pro XbxTable 1CompoundNo.174 Xad Val Xct Pro Xbx 5 17S Xau Val Xct Pro Xbx The symbols Xaa in Table 1 represent the following amino acids or residues thereof: 10 Xaa: N-methyl-valine Xab: Prolyl N-benzylamide Xac: L-N-methyl-piperidine-2-carboxylic acid Xad: D-N-methyl-piperidine-2-carboxylic acid Xae: N-methyl-L-proline 15 Xaf : N-methyl-L-thiazolidine-4-carboxylic acid Xag: N,N-dimethylglycine Xah: L-proline Xai: L-piperidine-2-carboxylic acid Xak: 2- [Ν,Ν-dimethylamino] - isobutyric acid 20 Xal: L-thiazolidine-4-carboxylic acid Xam: N-propyl-D-piperidine-2-carboxylic acid Xan: L-3,4-didehydroproline Xao : D-piperidine-2-carboxylic acid Xap: proline tert.butylester 25 Xaq: N-ethyl-D-piperidine-2-carboxylic acid Xar: N-methyl- [2,2,5,5-tetramethyl] -L-thiazolidine-2 carboxylic acid-45Xas:Xat:Xau:Xav:Xaw:Xax:Xay:Xaz :Xba:Xbb:Xbc:Xbd:Xbe :Xbf:Xbg:Xbh:Xbi:Xbk:Xbi :Xbm:Xbn:Xbo:Xbp:N-isopropyl-D-piperidine-2-carboxylic acid N, N-dime thyl-2 -cyclopropyl-glyc ine N, N-dimethyl-2-ethyl-2-phenyl-glycine D-prolineN-methyl-D-prolineN, N-dimethyl-2-[2-fluoro] phenyl-glycine1- aza-[3,3,0]bicyclooctyl-5-carboxylic acidN,N-dimethyl-2-[4-fluoro]phenyl-glycineN-methyl- [2,2,5,5-tetramethyl]-thiazolidine-2carboxylic acid2- (R,S)-ethyl-2-phenyl-glycineD,L-1-aminoindane-1-carboxylic acidN,N-dimethyl-2-{R,S)-methyl-2-phenyl-glycine 2-[N,N-dimethylamino]indane-2-carboxylic acid5-[Ν,Ν-dimethylamino]-5,6,7,8-tetrahydronaphthalene- 5 -carboxylic acid N-isopropyl-2-(R,S)-ethyl-2-phenyl-glycine 1- [Ν,Ν-dimethylamino] indane-2-carboxylic acid N, N-dime thyl-2-propyl-2-phenyl-glycine N, N-dimethyl-2- [4-methoxy] phenyl-glyc ine N-methyl-3-hydroxy-D,L-valineN, N-dimethyl-D, L-2-isopropyl-2-phenyl-glycine proline-N-me thoxy-N-methyl-amide N-methyl-piperidine-2-carboxylic acid proline-isopropylamideXbq: proline-isoxazolidinyl Xbr: proline-N-methoxy-N-benzylamide Xbs: N-methyl-D,L-proline Xbt: proline-[5-phenyl]isoxazolidinyl 5 Xbu: N-methyl-1,2,3,4-tetrahydroisoquinoline-lcarboxylic acid Xbv: N-methyl-azetidine-2-carboxylic acid Xbw: N-isopropyl-azetidine-2-carboxylic acid Xbx: proline-tert-butylamide 10 Xby: Ν,Ν-dimethyl-[O-methyl]serine Xbz: Ν,Ν-dimethyl-[O-methyl]threonine Xca: N-methyl-1,2,3,4-tetrahydroisoquinoline-3carboxylic acid Xcb: proline-pentyl(3)amide 15 Xcc: proline-(R)-phenethylamide Xcd: proline-(S)-phenethylamide Xce: 1- [Ν,Ν-dimethylamino] cyclohexyl-1-carboxylic acid Xcf: 1- [N, N-dimethylamino] cyclopentyl-l-carboxylic acid 20 Xcg: 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acidXch:CHjV CHj CHj-tf--48XcqXcrXcsXctL-2-tert-butyl-glycine N-methyl-L-IsoleucineTable 2: Results of FAB-MS analysis of selected compoundsCompound No. Mol. weight measured 1 S39 2 S3 9 3 S27 4 703 5 S25 6 Sil ' 7 S25 8 S25 10 667 12 625 13 606 14 653 IS 699 IS 667 17 639 18 639 19 643 20 611 21 599 22 693 23 693Compound No. Mol. weight measured 24 651 25 693 26 693 27 699 28 675 29 673 30 689 31 689 32 701 33 701 34 715 35 717 36 701 37 701 38 717 39 717 40 705 41 705 42 643 43 715 44 703 45 579 46 593 47 593 48 577 49 591 50 591 51 591 52 655 53 667 54 657 55 657 56 687 57 611 58 639 59 639 60 667 61 687 62 669 63 669 64 605 65 605Compound No. Mol. weight measured 66 591 67 643 68 657 69 637 70 687 71 605 72 605 73 655 74 669 75 683 76 703 77 703 78 683 79 697 80 697 81 731 82 731 83 731 84 719 85 719 86 645 87 645 88 685 89 685 90 717 91 717 92 679 93 679 94 591 95 591 96 655 97 655 93 731 99 719 100 651 Ϊθ1 651 102 713 103 713 104 713 105 666 106 653 107 687Compound No. Mol. weight measured 108 687Example 5 Evaluation of Biological ActivityIn vitro MethodologyCytotoxicity was measured using a standard methodology for adherent cell lines, such as the microculture tetrazolium assay (MTT). Details of this assay have been published (Alley, M.C. et al., Cancer Research 48: 589-601, (1988)). Exponentially growing cultures of HT-29 colon carcinoma cells were used to make microtiter plate cultures. Cells were seeded at 5000-20,000 cells per well in 96-well plates (in 150 mL of media) , and grown overnight at 37 C. Test compounds were added, in 10-fold dilutions varying from 10“4M to 10~10M. Cells were then incubated for 48 hours. To determine the number of viable cells in each well, the MTT dye was added (50 mL of a 3 mg / mL solution of 3-(4,5-dimethylthiazol-2-yl) -2,5diphenyltetrazolium bromide in saline). This mixture was incubated at 37°C for 5 hours, and then 50 mL of 25% SDS, pH 2, was added to each well. After an overnight incubation, the absorbance of each well at 550 nm was read using an ELISA reader. The values for the mean + / - SD of data from replicated wells were calculated, using the formula % T / C (% viable cells treated / control). The concentration of test compound which gives a T / C of 50% growth inhibition was designated as the ICS0.Table 3 presents the ICS0values determined in the HT29 assay for a series of compounds of the invention.-52Table 3Compound No. HT-29 CICSO] 1 4.7 x 10’a 2 6.8 χ IO’10 3 3.5 χ 10’9 4 1.2 χ 10'9 5 5.0 x 10-9 Θ 5.1 x IO*7 10 1.3 x IO'7 12 3.7 χ 10’7 13 1.0 x io-5 14 1.5 χ 10’9 15 1.7 χ IO’7 16 7.3 x IO’10 17 6.3 χ IO’9 1Θ 8.8 x IO’9 22 6.4 x IO'7 24 2.8 x 10'a 27 3.7 χ 10’9 28 4.9 x 10'a 29 3.5 x IO’9 30 6.1 x IO9 31 2.0 χ IO’7 32 8.5 χ 10’7 33 1.2 x 1O'S 34 5.0 x IO'9Compound No. HT-29 [ICsoi 35 1.4 X 10'7 36 6.2 X 10’9 37 1.9 x 10'7 38 7.3 x 10'7 39 2.5 x IO*8 40 5.6 x 10‘7 41 7.3 x 10'fi 42 3.4 x IO’7 43 5.9 X 10’8 44 4.8 x 10” 45 5.6 X 1Q~8 46 7.2 X 10’7 47 2.3 X IO'8 . 4a 2.5 x 10‘e 49 8.8 X IO*8 50 8.9 x 10'® 51 4.6 x 10‘8 52 3.4 x IO'7 53 5.0 x IO’9 54 4.2 x 10’9 55 5.6 x 10“8 57 2.5 x IQ*8 58 6.3 x 10’8 59 1.9 x IO'7 60 1.8 x IO'95325Compound No. HT-29 (ICSOI 62 9.9 x 10'a 63 5.6 x 10’a 64 1.7 x 10's 65 9.7 x IO'0 66 3.4 x IO’7 67 3.4 x 10’7 68 4.2 X IO'7 70 7.1 x 10~* 72 1.2 X 10’7 73 1.4 x 10’9 74 5.1 x IO’8 75 8.5 x IO’7 76 2.3 x IO'10 77 7.2 X IO-9 78 4.3 x IO'9 79 1.7 x 10‘* 80 6.7 x 10*a 81 1.3 x 10-7 82 1.1 X IO’8 83 1.3 x IO'7 84 1.2 X 10’* 85 9.5 x 10’* 90 9.3 x IO’10 91 8.3 x IO10 92 1.5 x 10'*Compound No. HT-29 [IC50] 93 1.8 X 10’s 94 3.0 x 1O'S 95 1.1 x 10'®· 96 1.7 χ 10-9 97 3.2 x IQ*8 98 6.0 x 10’9 99 3.8 x 10‘* 100 2.3 x 10*s 101 2.1 X 10'fi 102 1.2 x IO’7 103 1.1 X io-7 104 3.5 X 10** 105 1.8 x IO8 106 9.7 x IO'8 108 7.1 x 10’*5SIn vivo MethodologyCompounds, of this invention may be further tested in 20 any of the various preclinical assays for in vivo activity which are indicative of clinical utility. Such assays are conducted with nude mice into which tumor tissue, preferably of human origin, has been transplanted (*'xenograft ed) , as is well known in this field. Test compounds are evaluated for their anti-tumor efficacy following administration to the xenograft-bearing mice.More specifically, human tumors grown in athymic nude mice can be transplanted into new recipient animals, using-56tumor fragments which are about 50 mg in size. The day of transplantation is designated as day 0. Six to ten days later, the mice are treated with the test compounds given as an intravenous or intraperitoneal injection, in groups of 5-10 mice at each dose. Compounds are given daily for 5 days, 10 days or 15 days, at doses from 10-100 mg / kg body weight. Tumor diameters and body weights are measured twice weekly. Tumor masses are calculated using the diameters measured with Vernier calipers, and the formula:(length x width2) / 2 = mg of tumor weightMean tumor weights are then calculated for each treatment group, and T / C values are determined for each group relative to the untreated control tumors.-57EQUIVALENTSThose skilled in the art will recognize or be able to ascertain using no more than routine experimentation manyequivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed in the scope of the following claims.

Claims

1. A compound of the formula 5 A-B-D-E-F- (G) r- (K) a-L, wherein A is a proline derivative of Formula IIa, (Ha), wherein na is 0 to 3; Ra is hydrogen, or unsubstituted or fluorine-substituted normal, branched or cyclic Cx-C3-alkyl; Rxa is hydrogen, 15 Cx-C3-alkyl, phenyl, or substituted phenyl; or Ra and R1* together form a propylene bridge; and R2a, R3a, R4a and Rsa are each, independently, hydrogen or alkyl; or an α-amino acid derivative of Formula III wherein Ra is hydrogen or unsubstituted or fluorinesubstituted Cj-Ca-alkyl, R\ is C1“C4-alkyl; R6a is alkyl, substituted alkyl, alkenyl, phenyl or S substituted phenyl; or R\ is an alkyl group and R6a is CL-C6-alkyl, cycloalkylmethyl, benzyl or substituted benzyl; and R\ is hydrogen or alkyl; or 10 an α-amino acid derivative of Formula IVa, wherein ma is 1 or 2; R7a is hydrogen or alkyl; Ra is hydrogen, or unsubstituted or fluorine15 substituted alkyl; or an α-amino acid derivative of Formula Va, (Va), wherein R7a is hydrogen or alkyl and Ra is hydrogen, or unsubstituted or fluorine substituted alkyl; or wherein Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; R*a is hydrogen, alkyl, phenyl, or substituted phenyl; or Ra and r1* together form a propylene bridge; and Xa is hydroxy, alkoxy or fluorine; or wherein Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; Rxa is hydrogen, alkyl, phenyl, or substituted phenyl; or Ra and 10 Rxa together form a propylene bridge; and R2a, R3a, R4a and Rsa are each, independently, hydrogen or alkyl; or O -62wherein Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; or a 2-azabicyclo[2.2.1]heptane-3-carboxylic acid 5 derivative of Formula IXa, (IXa). wherein the 3-carbonyl moiety is in the endo or exo position, Za is a single bond or a double 10 bond, and Ra is hydrogen or unsubstituted or fluorine-substituted alkyl; or an OE-araino acid residue of Formula Xa, wherein ne is 1, 2 or 3, and R7a is hydrogen or alkyl and Ra is hydrogen, unsubstituted alkyl or fluorine-substituted alkyl; -63is a valyl, isoleucyl, allo-isoleucyl, norvalyl, 2-tert-butylglycyl or 2-ethylglycyl residue; or an α-amino acid residue of Formula IIb, (lib), wherein Rxb is hydrogen, and R2b is alkyl or alkenyl; or Rxb and R2b together form an isopropylidene group; D is an Ν-alkyl valyl, N-alkyl-2-ethylglycyl, Nalkyl-2-tert-butylglycyl, N-alkylnorleucyl, Nalkylisoleucyl, N-alkyl-allo-isoleucyl or Nalkylnorvalyl residue; or an α-amino acid residue of Formula IIa. Rd O wherein Ra is hydrogen, or unsubstituted or fluorine-substituted alkyl; Rxa is hydrogen; and R2a is alkyl, substituted alkyl or alkenyl; cr Rxd -64and Rad together form an isopropylidene group; or an α-amino acid residue of Formula IIId, II wherein nd is 1 or 2; R3d is hydrogen, alkyl or fluorine-substituted alkyl; and Xd is hydrogen,or nd is 1 and Xd is fluorine, hydroxy, methoxy, or ethoxy; E is a prolyl, thiazolidinyl-4-carbonyl, homoprolyl,or hydroxyprolyl residue; or an oc-amino acid residue of Formula IIe, IS II -65wherein ne is Ο, 1 or 2, Rxe is hydrogen, or unsubstituted or fluorine-substituted alkyl; R2e and R3e are each, independently, hydrogen or alkyl; R4e is hydrogen, hydroxy or alkoxy; and Rse 5 is hydrogen or fluorine; or ne is 1 and R3e and R4e together form a double bond; or ne is 1 and R4e and Rse together form a double-bonded oxygen diradical; or is 1 or 2 and Rxe and R2e together form a double bond; or an aminocyclopentanecarboxylic acid residue of Formula IIIe, (Hie), 15 wherein Re is alkyl and Rxe is hydrogen, or unsubstituted or fluorine-substituted alkyl; F is a prolyl, thiazolidinyl-4-carbonyl, homoprolyl or hydroxyprolyl residue; or an α-amino acid residue of Formula II wherein nf is 0, 1 or 2, R1i is hydrogen, or unsubstituted or fluorine-substituted alkyl; R2f and R3f are each, independently, hydrogen or methyl; R*f is hydrogen, hydroxy, alkoxy, or fluorine; RSf is·hydrogen or fluorine; or nf is 1 and R3f and R4f together form a double bond; or nf is 1 and R*f and Rsf together form a double-bonded oxygen diradical; or nf is 1 or 2 and Rxf and R2f together form a double bond; or a 2- or 3-aminocyclopentanecarboxylic acid residue of Formula Illf, O wherein Rf is alkyl and Rxf is hydrogen, or unsubstituted or fluorine-substituted alkyl; or an N-alkylglycyl or N-alkylalanyl residue; -6Ίis an α-amino acid residue of Formula ΙΙσ, R2 HN GU c II wherein Rxg is hydrogen or alkyl and R2g is hydrogen, alkyl, arylalkyl, heteroarylalkyl, phenyl or substituted phenyl; or Rxg and R2g, together with the α-carbon atom, form a Cs-C6 ring or a benzo-fused Cs ring; is an a-amino acid of Formula ΙΙλ, R2 HN (no, cwherein R\ is hydrogen, or alkyl; and R2k is hydrogen, alkyl, arylalkyl, heteroarylalkyl, phenyl or substituted phenyl; or Rxg and R2g, together with the α-carbon atom, form a cyclopentane ring or a benzo-fused cyclopentane ring; L is a substituted or unsubstituted amino, hydrazido, aminoxy or oximato group; and r and s are, independently, 0 or 1 provided that when s and r are each 0 and A is of formula IIa -i ι τ\ 1 τ·.'’ η < π Ί - c 5 -, τ25 -68each hydrogen, L is a substituted or unsubstituted amino or hydrazido group.

2. The compound of Claim 1 wherein A is a proline 5 derivative of Formula IIa; Ra is hydrogen, methyl, ethyl, normal propyl, isopropyl, cyclopropyl, 2fluoroethyl, 2,2,2-trifluoroethyl, l-methyl-2fluoroethyl, l-fluoromethyl-2-fluoroethyl, or 1methyl-2-fluoroethyl; Rxa is hydrogen, methyl, ethyl, 10 propyl, phenyl, or substituted phenyl, wherein the phenyl substituents comprise one or more alkyl, alkoxy, trifluoromethyl or nitro groups; or Ra and Rla together form a propylene bridge; and R2a, R3a, R4a and Rsa are each, independently, hydrogen or methyl.

3. The compound of Claim 1 wherein A is an α-amino acid residue of Formula IIIa, wherein Ra is hydrogen, methyl, ethyl, normal propyl, isopropyl, cyclopropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, 1-methyl-220 fluoroethyl, 1-fluoromethyl-2-fluoroethyl, or 1methyl-2-fluoroethyl; R\ is a C1~C3-alkyl group; Rea is methoxymethyl, 1-methoxyethyl, vinyl, 1methylvinyl, 1-trifluoromethylvinyl, 1trif luoromethylethyl, l-trifluoromethyl-2,2,225 trifluoroethyl, 1,1-di methyl hydroxymethyl, phenyl or substituted phenyl, wherein the phenyl substituents comprise one or more halogen atoms or one or more Cx-C4-alkyl, methoxy, trifluoromethyl or nitro groups; or Rxa is C^^-alkyl and Rfia is C1-C6-alkyl, 30 cycloalkylmethyl, benzyl or substituted benzyl, wherein the benzyl substituents comprise one or more halogen atoms, or one or mere Cx-C4-alkyl, methoxy, -69ethoxy, trifluoromethyl or nitro groups; and R7a is methyl, ethyl or isopropyl. The compound of Claim 1 wherein A is an a-amino acid residue of Formula IVa, wherein R7a is methyl, ethyl or isopropyl; and Ra is hydrogen, methyl, ethyl, npropyl, isopropyl, cyclopropyl, 2-fluoroethyl, 2,2,2trifluoroethyl, 1-methyl-2-fluoroethyl, 1fluoromethyl-2-fluoroethyl, or l-methyl-2-fluoroethyl. The compound of Claim 1 wherein A is an a-amino acid residue of Formula Va, wherein R7a is methyl, ethyl or isopropyl and Ra is hydrogen, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, 2-fluoroethyl, 2,2,2trifluoroethyl, l-methyl-2-fluoroethyl, 1fluoromethyl-2-fluoroethyl, or l-methyl-2-fluoroethyl. The compound of Claim 1 wherein A is .an α-amino acid residue of Formula VIa, wherein Ra is hydrogen, methyl, ethyl, normal propyl, isopropyl, cyclopropyl, 2-fluoroethyl, 2,2,2-trifluoroethyl, l-methyl-2fluoroethyl, 1-fluoromethyl-2-fluoroethyl, or 1methyl-2-fluoroethyl; Rxa is hydrogen, methyl, ethyl, propyl, phenyl, or substituted phenyl, wherein the phenyl substituents comprise one or more alkyl, alkoxy, trifluoromethy1 or nitro groups; or Ra and R3^ together form a propylene bridge; and Xa is a hydroxy, methoxy, or ethoxy group, or a fluorine atom. -707. The compound of claim 1, wherein L is a substituted or unsubstituted amino, or hydrazido.

8. A pharmaceutical composition comprising a compound of Claim 7 and a pharmaceutically acceptable carrier or diluent.

9. The composition of Claim 8 wherein L is an amino group of Formula II1Z wherein R\ is a hydrogen atom, a normal or branched, saturated or unsaturated Cj-Cjg-alkoxy group, a substituted or unsubstituted aryloxy group, a substituted or unsubstituted aryl C^Cg-alkoxy group, a substituted or unsubstituted aryloxy-C1-C6-alkoxy group, wherein the aryl substituents comprise one or more halogen atoms or one or more C1-C4-alkyl, methoxy, ethoxy, trifuloromethyl, dioxymethylene, or nitro groups; or a heteroaryl-C1-C6-alkoxy group; and is a hydrogen atom, a normal or branched Cj-C^alkyl group, a normal branched C^Cjg alkenyl group, a C3-C80-cycloalkyl group, an aryl group or a substituted aryl group, wherein the aryl substituents comprise one or more halogen atoms, or one or more C1-C4-alkyl, methoxy, ethoxy, trifluoromethyl, cyano or nitro groups, a Cj-CT-alkoxycarbonyl group, a dioxymethylene group, a Ci-C-j-alkylsulfonyl group, an amino group or a Ci-Cg-dialkylamino group; a heteroaryl group or a substituted heteroaryl group derived from imidazole, -71isoxazole, isothiazole, thiazole, oxazole, pyrazole, thiophene, furan, pyrrole, 1,2,4- or 1,2,3-triazole, pyrazine, indole, benzofuran, benzothiophene, indole, isoindole, indazole, quioline, pyridazine, pyrimidine, benzimidazole, benzopyran, benzothiazole, oxadiazole, thiadiazole or pyridine, wherein the heteroaryl substituents comprise one or more Ci-Cg-alkyl, hydroxyl or phenyl groups.

10. The compound of Claim 9 wherein R2X is of Formula IIX, —CH— (CHJaj — R\ I (III) R3i wherein alf is 0, 1, 2, 3, 4, or 5; R3i is methyl, ethyl, normal propyl or isopropyl; and R\ is a saturated or partially unsaturated carbocyclic system comprising from about 3 to about 10 carbon atoms, an aryl group or a substituted aryl group, wherein the aryl substituents comprise one or more halogen atoms, or one or more Ci-C4-alkyl groups, methoxy, ethoxy, trifluoromethyl, cyano or nitro groups, a Ci-C-j-alkoxycarbonyl group, a dioxymethylene group, a Ci-C-j-alkylsulfonyl group, an amino group or a C1-C6-dialkylamino group; a heteroaryl group or a substituted heteroaryl group derived from imidazole, isoxazole, isothiazole, thiazole, oxazole, pyrazole, thiophene, furan, pyrrole, 1,2,4- or 1,2,3-triazole, pyrazine, indole, benzofuran, benzothiophene, indole, isoindole, indazole, quinoline, pyridazine, pyrimidine, benzimidazole, benzopyran, benzothiazole, oxadiazole, thiadiazole or pyridine, wherein the heteroaryl substituents comprise one or more Ci-Cgalkyl, hydroxyl or phenyl groups. -7211. The compound of Claim 9 wherein R2X is of Formula ΙΙΙΧ, — (CH2)2—W— R5! (IIIJ , wherein Wx is an N(R%) group, an oxygen atom or a sulfur atom; R\ and R\ are each, independently, a hydrogen atom or a C^C^-alkyl, C3-C7cycloalkyl, aryl, arylmethyl, substituted aryl, or substituted arylmethyl group, wherein the aryl substituents comprise one or more halogen atoms, or one or more Cj-C^-alkyl groups, methoxy, ethoxy, trifluoromethyl, cyano or nitro groups, a C1-C7alkoxycarbonyl group, a dioxymethylene group, a C1-C7alkylsulfonyl group, an amino group or a Cj-Cgdialkylamino group; or R6X is a C1-C16-alkanoyl group or a benzoyl group.

12. The compound of Claim 9 wherein R2X is a monovalent radical of Formula IVj, — (CH2)b1“Z1 (IVJ , wherein bx is 2, 3, or 4 and Zx is a formyl, aminocarbonyl, hydrazinocarbonyl, cyclic acetal, cyclic thioacetal, acyclic acetal or acyclic thioacetal group.

13. The compound of Claim 9 wherein R2X is of Formula Vlz « C / \ — (CH2)b:-N R' H (VJ , -73wherein bj is 2, 3, or 4; and R\ is a polyglycol group of the formula -0-(CH2CH2O) ζ1-0Η3, wherein d1 is between about 2 and about 4, or between about 40 and about 90.

14. The compound of Claim 9 wherein R2! is of Formula VIlr and R% is a hydrogen atom, or a ^-0« alkanoyl, Cj-C4 alkyl, benzoyl, or benzyl group.

15. The compound of Claim 8 wherein at least one of r and s is 1, and L is an amino group of Formula IVj, wherein R2! and R\ are each, independently, hydrogen or Ci~C10-alkyl; or R21Z R\ and the α-carbon together form a C5-C6-carbocycle.

16. The compound of Claim 8 wherein L is a hydrazido group of Formula V2, -74-N—N R11! (VJ , wherein R12! is a hydrogen atom, a normal or branched Ci-Cgalkyl group, a C3-C8-cycloaikyl group, a C3-C8cycloalkyl-C1-C4-alkyl group, an aryl group, an arylC1-C4-alkyl group, or a substituted aryl or aryl-C1-C4alkyl group wherein the aryl substituents comprise one or more halogen atoms, or one or more methoxy, ethoxy, trifluoromethyl, dioxymethylene, nitro, cyano, Ci-C7alkoxycarbonyl, Cx-C-y-alkylsulfonyl, amino, or C1-C7dialkylamino groups; or a heteroaryl-C1-C4-alkyl group, wherein the heteroaryl group is derived from imidazole, pyrrole, thiophene, furan, thiazole, oxazole, pyrazole, 1,2,4- or 1,2,3-triazole, oxadiazole, thiadiazole, isoxazole, isothiazole, pyrazine, pyridazine, pyrimidine, pyridine, benzofuran, benzothiophene, benzimidazole, benzothiazole, benzopyran, indole, isoindole, indazole or quinoline and the heteroaryl substituents comprise one or more Cj-Cg-alkyl, hydroxyl or phenyl groups; and R11! is a hydrogen atom; or r is 1, s is 1 or both r and s are 1, and R11! is a normal or branched Ci-Cgalkyl group, a C3-C8-cycloalkyl group, a C3-C8cycloalkyl-C1-C4-alkyl group, an aryl C1-C4-alkyl group, an aryl group or a substituted aryl-Ci-C4-alkyl or aryl group, wherein the aryl substituents comprise one or more halogen atoms, or one or more C1-C4-alkyl groups, methoxy, ethoxy, trifluoromethyl, cyano or nitro groups, a Ci-C-j-alkoxycarbonyl group, a dioxymethylene group, a Cj-C-j-alkylsulfonyl group, an amino group or a Ci-Cg-dialkylamino group; a hetercaryl group a -7510 a heteroaryl-Ci -C4 -alkyl group or a substituted heteroaryl or heteroaryl-Ci -C4 -alkyl group derived from imidazole, isoxazole, isothiazole, thiazole, oxazole, pyrazole, thiophene, furan, pyrrole, 1,2,4- or 1,2,3-triazole, pyrazine, indole, benzofuran, benzothiophene, indole, isoindole, indazole, quinoline, pyridazine, pyrimidine, benzimidazole, benzopyran, benzothiazole, oxadiazole, thiadiazole or pyridine, wherein the heteroaryl substituents comprise one or more Ci -Cg -alkyl, hydroxyl or phenyl groups; or R11! and R12i together form a propylene bridge or a butylene bridge.

17. The use of a compound of claim 7 for the manufacture of a medicament for inhibiting formation of solid tumor in a 15 mammal.

18. The use of a compound of claim 7 for the manufacture of a medicament for treating cancer in a mammal.20 19. The use of a compound of claim 7 for the manufacture of a medicament for treating solid tumor in a mammal.